# Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor/tezacaftor/ivacaftor therapy

This repository contains code and subset data files generated and used in analysis in the publication of this manuscript. Please contact Jennifer Bomberger (corresponding author; jbomb@dartmouth.edu) for other data availability.

### File list:
* <a href="https://github.com/yasminhilliam/sinus_ETI/blob/main/20240108_HILLIAM_data_analysis.md">20240208_HILLIAM_data_analysis.md: Bash and R code used in the preparation of this manuscript</a>.<br>
* <a href="https://github.com/yasminhilliam/sinus_ETI/blob/main/20240208_HILLIAM_sinus_data.csv">20240208_HILLIAM_sinus_data.csv</a>: OTU and abundance data table from subjects with pre- and post-ETI samples.<sup><span>&#8224;</span></sup><br>
* <a href="https://github.com/yasminhilliam/sinus_ETI/blob/main/20240208_HILLIAM_paired_data.csv">20240208_HILLIAM_paired_data.csv</a>:  OTU and abundance data table from subjects with paired sinus and sputum samples.<sup><span>&#8224;</span></sup>
<br>
<br>
<span>&#8224;</span> Data in these tables have been processed through QIIME2, phyloseq, and vegan and then filtered to only include samples from relevant subjects.
